Have a feature idea you'd love to see implemented?
Let us know!
BTAI BioXcel Therapeutics Inc
Price (delayed)
$0.3567
Market cap
$15.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.15
Enterprise value
$79.46M
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically
Highlights
BTAI's EPS has surged by 71% year-on-year and by 39% since the previous quarter
BioXcel Therapeutics's net income has surged by 66% YoY and by 34% QoQ
BTAI's revenue has surged by 83% year-on-year but it is down by 5% since the previous quarter
The equity has dropped by 111% year-on-year and by 15% since the previous quarter
BTAI's gross margin has dropped by 80% year-on-year and by 74% since the previous quarter
Key stats
What are the main financial stats of BTAI
Market
Valuations
Earnings
Shares outstanding
42.75M
Market cap
$15.25M
Enterprise value
$79.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.91
Revenue
$2.28M
Gross profit
$250,000
Net income
-$71M
EBIT
-$56.46M
EBITDA
-$56.15M
Free cash flow
-$84.08M
Per share
Balance sheet
Liquidity
EPS
-$2.15
EPS diluted
-$2.15
Free cash flow per share
-$1.98
Book value per share
-$2.1
Revenue per share
$0.05
TBVPS
$1.15
Total assets
$48.89M
Total liabilities
$134.53M
Debt
$104.6M
Equity
-$85.63M
Working capital
$22.24M
Debt to equity
-1.22
Current ratio
1.87
Quick ratio
1.58
Net debt/EBITDA
-1.14
Margins
Efficiency
Dividend
EBITDA margin
-2,467.2%
Gross margin
11%
Net margin
-3,119.3%
Operating margin
-3,366.7%
Return on assets
-105%
Return on equity
N/A
Return on invested capital
-67.7%
Return on capital employed
-242%
Return on sales
-2,480.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BTAI stock price
How has the BioXcel Therapeutics stock price performed over time
Intraday
-7.06%
1 week
-24.32%
1 month
-13.44%
1 year
-86.44%
YTD
-4.6%
QTD
-4.6%
Financial performance
How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$2.28M
Gross profit
$250,000
Operating income
-$76.63M
Net income
-$71M
Gross margin
11%
Net margin
-3,119.3%
BTAI's revenue has surged by 83% year-on-year but it is down by 5% since the previous quarter
BTAI's net margin has surged by 82% year-on-year and by 30% since the previous quarter
BTAI's gross margin has dropped by 80% year-on-year and by 74% since the previous quarter
BTAI's operating margin has soared by 80% YoY and by 26% QoQ
Growth
What is BioXcel Therapeutics's growth rate over time
Valuation
What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
6.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.91
BTAI's EPS has surged by 71% year-on-year and by 39% since the previous quarter
The equity has dropped by 111% year-on-year and by 15% since the previous quarter
BTAI's revenue has surged by 83% year-on-year but it is down by 5% since the previous quarter
The price to sales (P/S) is 82% lower than the last 4 quarters average of 36.2
Efficiency
How efficient is BioXcel Therapeutics business performance
BTAI's return on sales has surged by 85% year-on-year and by 36% since the previous quarter
BioXcel Therapeutics's ROIC has soared by 74% YoY and by 43% from the previous quarter
BioXcel Therapeutics's return on assets has increased by 22% YoY and by 22% QoQ
Dividends
What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BTAI.
Financial health
How did BioXcel Therapeutics financials performed over time
The total assets is 64% less than the total liabilities
The total assets has plunged by 51% YoY and by 25% from the previous quarter
BTAI's quick ratio is down by 31% year-on-year and by 24% since the previous quarter
The equity has dropped by 111% year-on-year and by 15% since the previous quarter
BioXcel Therapeutics's debt to equity has soared by 50% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.